Azmacort Inhalation Aerosol is a metered-dose inhaler used for maintenance treatment of asthma and is not a bronchodilator and is not indicated for rapid relief of bronchospasm or other acute episodes of asthma. The main ingredient is a inhaled corticosteroid.
Particular care is needed in patients who are transferred from systemically taken (by mouth) corticosteroids to Azmacort Inhalation Aerosol because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to aerosolized steroids in recommended doses.
Localized infections with Candida albicans (thrush) have occurred infrequently in the mouth and pharynx.
Other common side effects may include sinusitis, headache, back pain, diarrhea, vomiting, bursitis, dry mouth, rash, chest congestion and urinary tract infection.
Patients should use inhaled corticosteroids at regular intervals as directed. Significant improvement in asthma may occur by 1 week, but maximum benefit may not be achieved for 2 weeks or more. The patient should not increase the prescribed dosage but should contact the physician if symptoms do not improve or if the condition worsens.
NOTE: Azmacort Contains CFC -12, a substance which harms public health and the environment by destroying ozone in the upper atmosphere.
a. asthma. The
It may no longer be available after Decemeber 2008.
Adapted from Source: http://www.fda.gov/cder/foi/label/2008/018117s042lbl.pdf